32 results
8-K
EX-1.1
FATE
Fate Therapeutics Inc
20 Mar 24
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
5:32pm
Disclosure Package or the Prospectus.
(vv) Anti-Corruption and Anti-Bribery Laws. Neither the Company nor any of its subsidiaries, nor any director, officer … of 1977, as amended (the “FCPA”), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, authorized
8-K
EX-1.1
5py3g1ra2tw6
4 Nov 21
Entry into a Material Definitive Agreement
4:59pm
S-3ASR
EX-1.2
mx51weg0
4 Nov 21
Automatic shelf registration
4:56pm
8-K
EX-1.1
mt1jlcz
8 Jan 21
Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock
4:02pm